RESUMENCaso clínico: Se describe una mujer de 16 años con epilepsia severa que desarrolló una hemianopsia homónima izquierda después de tomar topiramato 125 mg durante 12 semanas y una mujer epiléptica de 24 años que presentó una maculopatía bilateral después de tomar 150 mg de topiramato durante 8 semanas. Discusión: Se identifican dos reacciones oculares adversas al topiramato. Ambas precisan retirar el tratamiento, aunque la maculopatía por topiramato es irreversible.Palabras clave: Topiramato, hemianopsia homóni-ma, maculopatía. COMUNICACIÓN CORTA ABSTRACTCase reports: We describe 2 patients who developed ocular side effects during treatment with topiramate. One was a 16-year-old woman with generalized seizures who developed a homonymous hemianopia after using topiramate 125 mg per day for 12 weeks, and the other was a 24-year-old epileptic female who developed a bilateral maculopathy after using topiramate 150 mg per day for 8 weeks. Discussion: We identified two severe ocular adverse reactions from topiramate. Both reactions necessitated discontinuing the treatment, but the topiramate-associated maculopathy was irreversible (Arch Soc Esp Oftalmol 2006; 81: 345-348).

Case report: We describe a 65-year-old asymptomatic woman with unilateral optic disc edema. Laboratory testing revealed a very marked positive PPD (25 mm) with dermatolysis. Anti-tuberculosis therapy resulted in complete resolution. Discussion: Tuberculosis should be considered in the diagnosis of papillitis, even in asymptomatic patients (Arch Soc Esp Oftalmol 2006; 81: 37-40).

Case report: We report a 59-year-old patient with difficulty in visual perception, difficulty reading and episodes of dyschromatopsia. The ocular examination was unremarkable. Structural neuro-imaging and neuro-opthalmology tests were normal. Positron emission tomography scanning showed decreased metabolism in the parieto-occipital cortex bilaterally. Several months later the patient developed Alzheimer´s disease. Discussion: Visual symptoms may be the first manifestation of Alzheimer´s disease (Arch Soc Esp Oftalmol 2006; 81: 169-172).

No abstract

No abstract